Interaction of cisapride with the human cytochrome P450 system: Metabolism and inhibition studies

Drug Metabolism and Disposition

Volumn 28, Issue 7, 2000, Pages 789-800

  Desta, Zeruesenay ^a   Soukhova, Nadia ^a   Mahal, Subena K ^a   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; FURAFYLLINE; ISOPROTEIN; KETOCONAZOLE; OMEPRAZOLE; QUERCETIN; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; METABOLIC INHIBITION; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CISAPRIDE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GASTROINTESTINAL AGENTS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; RECOMBINANT PROTEINS;

EID: 0033912432     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abdel-Rahman SM, Lan L, Yasuda K and Leeder JS (2000) Cisapride is an inhibitor but not a substrate for human P-glycoprotein. Clin Pharmacol Ther 67:97.
2. Backman JT, Kivisto KT, Olkkola KT and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58.
3. Bedford TA and Rowbotham DJ (1996) Cisapride: Drug interactions of clinical significance. Drug Saf 15:167-175.
4. Bran S, Murray WA, Hirsch IB and Palmer JP (1995) Long QT syndrome during high-dose cisapride. Arch Intern Med 155:765-768.
5. Broly F, Libersa C, Lhermitte M, Bechtel P and Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28:29-36.
6. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G and Wadstedt G (1997) Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther 282:220-227.
7. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
8. Desai PB, Duan JZ, Zhu YW and Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424.
9. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW and Flockhart DA (1998) Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 285:428-437.
10. Drolet B, Khalifa M, Daleau P, Hamelin BA and Turgeon J (1998) Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97:204-210.
11. Eichelbaum M (1988) Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 37:93-96.
12. Food and Drug Administration (FDA) (2000) FDA updates warnings for cisapride. FDA Talk Paper, pp 1-25.
13. Gorski JC, Jones DR, Wrighton SA and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
14. Hoover CA, Carmichael JK, Nolan PE Jr and Marcus FI (1996) Cardiac arrest associated with combination cisapride and itraconazole therapy. Cardiovasc Pharmacol Ther 1:255-258.
15. Ishida M, Otani K, Yasui N, Inoue Y and Kaneko S (1997) Possible interaction between cisapride and bromperidol. Prog Neuropsychopharmacol Biol Psychiatry 21:235-238.
16. Josefson D (1998) FDA warns about heartburn drug. Br Med J 317:101.
17. Kivisto KT, Lilja JJ, Backman JT and Neuvonen PJ (1999) Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 66: 448-453.
18. Ko JW, Sukhova N, Thacker D, Chen P and Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862.
19. Lin JH, Chiba M and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
20. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
21. McCallum RW, Prakash C, Campoli-Richards DM and Goa KL (1988) Cisapride: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36:652-681.
22. Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M, Woestenborghs R and Heykants J (1988) Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 16:403-409.
23. Michiels M, Monbaliu J, Hendriks R, Geens R, Woestenborghs R and Heykants J (1987) Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. Arzneimittelforschung 37:1159-1167.
24. Mihara K, Otani K, Yasui N, Ishida M, Kondo T, Suzuki A, Furukori H, Nagashima U, Kaneko S and Inoue Y (1999) No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Ther Drug Monit 21:297-300.
25. Owen JR and Nemeroff CB (1998) New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 7 (Suppl I):24-321.
26. Pollard HB, Menard R, Brandt HA, Pazoles CJ, Creutz CE and Ramu A (1978) Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 86:761-763.
27. Preechagoon Y and Charles BG (1995) Analysis of cisapride in neonatal plasma using high-performance liquid chromatography with a base-stable column and fluorescence detection. J Chromatogr B Biomed Appl 670:139-143.
28. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
29. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
30. Thomas AR, Chan LN, Bauman JL and Olopade CO (1998) Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotheraphy 18:381-385.
31. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, and Carithers RL (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556.
32. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Taxicol 38:389-430.
33. Tonini M, de Ponti F, Di Nucci A and Crema F (1999) Review article: Cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 13:1585-1591.
34. van Haarst AD, van't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J. Coene MC and Cohen AF (1998) The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64:542-546.
35. Vandenplas Y, Belli DC, Benatar A, Cadranel S, Cucchiara S, Dupont C, Gottrand F, Hassall E, Heymans HS, Kearns G, Kneepkens CM, Koletzko S, Milla P, Polanco I and Staiano AM (1999) The role of cisapride in the treatment of pediatric gastroesophageal reflux. J Pediatr Gastroenterol Nutr 28:518-528.
36. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL and Dreyer NA (1999) The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 107:356-362.
37. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
38. Wysowski DK and Bacsanyi J (1996) Cisapride and fatal arrhythmia. N Engl J Med 335:290-291.